PTPA and neoplasm: Notably, unlike other tumor suppressors that are inactivated by genetic mutation, PP2A is primarily disabled by non-genetic mechanisms, including upregulation of endogenous inhibitors (e.g., SET, CIP2A) and posttranslational modification (e.g., L309 carboxymethylation) (26, 28, 29).